Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity

One of the critical issues that should be addressed in the development of a BCG-based HIV vaccine is genetic plasmid stability. Therefore, to address this issue we have considered using integrative vectors and the auxotrophic mutant of BCG complemented with a plasmid carrying a wild-type complementi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahant, Aakash, Saubi, Narcís, Eto, Yoshiki, Guitart, Núria, Gatell, Josep Ma, Hanke, Tomáš, Joseph, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557246/
https://www.ncbi.nlm.nih.gov/pubmed/28426273
http://dx.doi.org/10.1080/21645515.2017.1316911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557246/
https://www.ncbi.nlm.nih.gov/pubmed/28426273
http://dx.doi.org/10.1080/21645515.2017.1316911

Ejemplares similares